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The role of osmolality in the incidence of contrast induced
nephropathy: A systematic review of angiographic contrast
media in high risk patients.
Background. The role of osmolality of contrast media
(CM) in the pathogenesis of contrast-induced nephropathy
(CIN) has been suggested by studies comparing high osmo-
lality CM (>1500 mOsm/kg) with low-osmolality CM (550–
850 mOsm/kg), and by the results of a recent comparison of
a CM isotonic to plasma (iodixanol, 290 mOsm/kg) with a low-
osmolality CM (iohexol, 844 mOsm/kg) in high-risk patients
undergoing cardiac or peripheral angiography.
Methods. Using prospectively defined search criteria, we per-
formed a systematic overview of prospective, randomized, con-
trolled studies of CIN in renally impaired patients receiving
intra-arterial doses of iodixanol or low-osmolality, nonionic
CM, and conducted a systematic review of the data from those
studies to determine whether the osmolality of CM was predic-
tive of CIN incidence.
Results. Seventeen primary studies met the selection criteria,
for a total of 1365 patients. Overall, the incidence of CIN was
16.8%. A multivariate logistic regression model showed that the
risk of CIN is similar with the iso-osmolality iodixanol and the
low-osmolality iopamidol (796 mOsm/kg). The risk of CIN was
significantly lower with iodixanol and iopamidol compared to
iohexol. The incidence of CIN with iohexol was also significantly
higher than with iopamidol, despite their similar osmolalities.
Conclusion. These data suggest that factors other than osmo-
lality play a significant role in the pathogenesis of CIN, at least
for agents with osmolalities of 800 mOsm/kg or less.
Contrast-induced nephropathy (CIN) is an acute de-
cline in renal function after administration of an iodinated
contrast agent in the absence of an alternative cause [1, 2].
Development of CIN is defined by a transient increase in
concentration of serum creatinine (SCr) relative to base-
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line levels. The definition of the point at which a patient
develops CIN varies from clinical study to clinical study.
Definitions range from absolute (0.5 to 1.0 mg/dL) to rel-
ative (10%, 25%, 50%, or 100%) increases over base-
line levels. In the vast majority of clinical trials, however,
CIN has been defined as a relative rise in SCr ≥25%, or
as an absolute increase ≥0.5 mg/dL from baseline [3, 4].
Based on this definition, the overall incidence of CIN is
estimated to be 0.6% to 2.3% [5]. In patients with cardio-
vascular pathology undergoing angiography procedures,
the incidence of CIN is higher, and ranges from 3.3% to
14.5% [6, 7]. Chronic kidney disease, defined as SCr sta-
bly ≥1.5 mg/dL, or a calculated or estimated creatinine
clearance (CrCl) <60 mL/min, is the most important fac-
tor for the development of CIN [1, 2, 6]. In the vast ma-
jority of cases, a rise in SCr occurs within 24 to 48 hours
of exposure to iodinated contrast media (CM), with a re-
turn to baseline or near baseline within 7 to 10 days [4, 8].
Dialysis as a result of CIN is required in 0.3% to 0.7% of
patients undergoing angiography [6, 7]. Almost every pa-
tient who develops acute renal failure requiring dialysis
shows a significant SCr rise already at 24 hours after the
exposure to iodinated contrast [9]. Patients who develop
contrast-induced acute renal failure are at significantly
higher risk of death, both in hospital and at 1 year [6, 10–
12]. The prognosis is particularly unfavorable in patients
with preexisting renal compromise [10, 11].
Contrast agents cause nephrotoxicity through direct
toxicity to tubular cells and renal medullary ischemia.
Previous meta-analyses of CM found that the use of
nonionic, low-osmolality versus ionic, high-osmolality
contrast agents diminished the risk of CIN in high-risk
patients [13–15]. This led to the generally accepted con-
cept that osmolality contributed to the nephrotoxicity
of CM, so-called “osmotoxicity.” Recently, a prospec-
tive, double-blind, randomized, multicenter trial (the
NEPHRIC study) provided further support for this
concept. The study patients had mild-to-moderate re-
nal failure (mean baseline SCr 1.5–1.6 mg/dL), diabetes,
and underwent cardiac or peripheral angiography. The
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Table 1. Chemical structure and physicochemical properties of iodine-based contrast agents
Chemical Osmotic Representative Osmolality Viscosity Viscosity
Ionicity structure class compounds (mOsm/kg) (cPs at 20◦C) (cPs at 37◦C)
Ionic Monomer High osmolality Diatrizoate, Meglumine (Renografin, Conray, Hypaque) 1400–1800 6 4
Dimer Low osmolality Ioxaglate (Hexabrix) 600 15 8
Nonionic Monomer Low osmolality Iohexol (Omnipaque), Iopamidol (Isovue) Ioversol (Optiray)
Iopromide (Ultravist)
600–850 9–21 5–10
Dimer Iso-osmolality Iodixanol (Visipque) 280 27 12
incidence of CIN was significantly lower with the iso-
osmolality agent iodixanol (290 mOsm/kg) compared to
the low-osmolality agent iohexol (844 mOsm/kg) [16].
Based on the results of this study, it has been suggested
that an iso-osmolality agent would be less likely to cause
renal injury to patients with preexisting renal impairment
compared to all low-osmolality CM. However, CM me-
dia differ in a number of other physicochemical charac-
teristics, including ionicity, viscosity, and molecular size
(monomer vs. dimer) (Table 1).
Several other studies have evaluated the nephrotoxi-
city of iso- and low-osmolality nonionic CM in patients
with preexisting renal failure, although these studies were
not designed as head-to-head comparison trials. There-
fore, we performed a systematic overview of all prospec-
tive studies of CIN in patients undergoing cardiac or
peripheral angiography, and analyzed the pooled data
from studies in patients with baseline renal insufficiency
to determine whether the available data support the os-
motoxicity concept. Specifically, we asked whether iso-
osmolality CM are associated with less nephrotoxicity
compared to all low-osmolality CM.
METHODS
We used the following strategies to identify the primary
studies to be included in the analysis: an electronic search
of medical databases and a review of the reference lists
from review articles that fulfilled our eligibility criteria.
Identification of systematic reviews
A total of 81 reviews on CIN following intravascu-
lar administration of iodinated CM were retrieved us-
ing an online search on MEDLINE and the following
key words: “contrast media,” “nephrotoxicity,” “review.”
Seven of these were selected for further assessment of
cited references.
Study identification
A systematic and comprehensive online search was
performed for publications printed from January 1991
to September 2004. A librarian undertook an iterative
process, for each database, to refine the search strategy
through testing of several search terms and incorpora-
tion of new search terms as new relevant citations were
identified. The search included the following databases:
EMBASE, MEDLINE, Biosis Previews, Derwent Drug
File, Pascal, SciScearch Cited Ref Sci.
A combination of the following key words was used:
“contrast/imaging medium/a,” “contrast/imaging agent,”
as well as individual nonionic contrast media nonpro-
prietary/proprietary names, “complications/reactions/
effects,” “contrast-induced nephropathy,” “nephropa-
thy,” “nephrotoxicity,” “chronic renal failure,” “chronic
renal insufficiency,” “renal/kidney impairment,” “creati-
nine,” “controlled clinical study.” A total of 1594 citations
were identified.
Selection of primary studies
The following criteria were prospectively defined to
select studies for inclusion in the review: (1) English lan-
guage; (2) publication in peer-reviewed journals; (3) ei-
ther randomized, double-blind comparisons of iodinated
contrast media, or prospective, randomized studies of the
safety and efficacy of measures to prevent CIN (hemofil-
tration, N-acetylcysteine, or other drugs); (4) the exact
number of patients who had received a specific nonionic
contrast agent (e.g., iodixanol, iohexol, iopamidol, etc.)
clearly reported; (5) the exact number of patients who
had received or not received any preventive measure
other than hydration clearly reported; (6) adequate hy-
dration before and after the procedure; (7) study pop-
ulations with mean baseline SCr levels between 1.5 and
3.5 mg/dL and/or mean baseline CrCl between 20 and 60
mL/min; (8) intra-arterial CM administration; (9) defini-
tion of CIN end point as an absolute increase ≥0.5 mg/dL
or a relative increase ≥25% in SCr over baseline at 1 to
7 days after the CM administration.
Due to the limited precision of the index terms used
by the online databases, an initial screening was per-
formed by one qualified reviewer to discard citations that
were clearly not pertinent (animal/in vitro studies, stud-
ies not related to contrast media, contrast media used for
glomerular filtration rate measurement, contrast media
pharmacokinetics, congress abstracts/posters). This pre-
liminary screening process yielded 145 potentially rel-
evant citations. Subsequently, two qualified reviewers
independently screened the titles and abstracts of each
of these, and if either reviewer believed that a citation
could be relevant, the full-text article was retrieved and
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the selection criteria were applied. At this step, citations
were excluded for the following reasons: editorials, let-
ters, reviews, re-published studies, administration route
different than intra-arterial. The full text of the remain-
ing 62 citations was retrieved for full review.
We masked the results (i.e., obscured them with a black
marker from the tables and text) of all publications se-
lected for full review. Two individuals independently eval-
uated each masked article to determine eligibility. All
disagreements were resolved by consensus. The consen-
sus process required individuals to discuss the reasoning
for their decisions. If one individual realized that she or
he had made an error, then the process was repeated.
Consensus was obtained in all cases, and therefore an
independent third adjudicator was never required to re-
solve disagreements.
Following the identification of the previously published
reviews and the selection of the primary studies, the ref-
erence section of both the systematic reviews and the
primary studies was reviewed to search for additional
primary studies that could have been missed by the elec-
tronic search. No additional relevant publications were
identified.
Patient selection
We evaluated only data from patients who had received
a nonionic contrast agent to avoid any potential contri-
bution of ionicity to nephrotoxicity. In case prospective,
randomized studies of the safety and preventive efficacy
of hemofiltration, N-acetylcysteine, or other drugs were
selected, we reviewed only the data from the placebo or
control arm of those studies to eliminate the confounding
effect of the preventative strategy.
Analysis
The data from the selected studies were pooled to-
gether overall and by the contrast agent used. For contin-
uous variables, the mean was calculated using the means
of each individual study weighted by the number of pa-
tients in that study. The standard deviation for the pooled
data was calculated using standard deviation from each
study with an assumption that all the studies had approx-
imately the same level of variability. When only mean
values were reported, a graphic display of standard devi-
ation versus mean was employed to interpolate the values
for the unknown standard deviation.
Baseline patient characteristics (i.e., age, gender, dia-
betes mellitus, CM dose, and baseline SCr) in CM groups
(iohexol, iodixanol, and iopamidol) were compared by
pairwise t tests (iodixanol vs. iohexol, iopamidol vs. io-
hexol, etc.) for continuous variables and a chi-square test
for categorical variables. Neither homogeneity testing
nor comparisons of CIN incidence were performed for
iopromide, iomeprol, ioxilan, and iopentol study groups
versus other study groups because the sample size of the
studies with these agents was too small.
The outcome chosen for analysis was the incidence of
CIN, defined in each study as a relative rise in SCr ≥25%,
or as an absolute increase ≥0.5 mg/dL from baseline. To
obtain the incidence rate of CIN, we pooled the CIN cases
in the different primary studies and then divided the num-
ber of CIN cases by the overall number of the selected
patients in the same studies.
The risk of CIN in CM was compared by a multivari-
ate logistic regression model, and odds ratios (OR) and
95% CIs were used to quantify the likelihood of hav-
ing CIN. This multivariate model was developed using
SAS software version 8.2 (Cary, NC, USA). The study-
level patient baseline characteristics, including age, gen-
der, percentage of patients with diabetes mellitus, volume
of CM administered, and baseline SCr, were treated as co-
variates. Goodness-of-fit of the logistic model was tested
using the Hosmer and Lemeshow test. For CM compar-
ison, the largest patient group (iohexol) was treated as
the reference group.
RESULTS
Selected studies
A schematic representation of the process used to se-
lect the studies included in this meta-analysis (primary
studies) is shown in Figure 1. Overall, this strategy iden-
tified 17 primary studies [13, 14, 16–30]. Thirteen of these
studies were placebo-controlled, randomized, double-
blind comparisons assessing the safety and efficacy of CIN
preventive measures (hemofiltration, N-acetylcysteine,
or other drugs) in patients with preexisting renal failure
[18–30]. Four studies were prospective, randomized com-
parisons of CIN incidence with different contrast agents
[13, 14, 16, 17].
Forty-five full-text publications were excluded for any
of the following reasons: incompletely reported renal lab-
oratory data in terms of parameters and/or duration of
follow-up; patient population with normal renal function
or with baseline serum creatinine above 3.5 mg/dL; con-
trast medium not identified or pooled by class; number
of patients receiving a specific contrast medium not re-
ported; investigations with the ionic dimer ioxaglate; dif-
ferent end point used to define CIN.
RESULTS
A total of 1365 patients met the selection criteria. The
baseline characteristics of the patients in the selected pri-
mary studies are shown in Table 2. In the NEPHRIC
study, 100% of patients had both diabetes mellitus and
mild-to-moderate renal insufficiency [16], while the per-
cent of diabetic patients in the other studies ranged be-
tween 15% and 64%. Three studies included patients
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Search results screened: 1594
Potentially relevant citations: 145
Citations selected for full-text review: 62
Primary studies identified: 17
Citations excluded: 1449 
Reasons: animal/in vitro studies, studies not related to CM,  
CM used for GFR measurement, CM pharmacokinetics, 
congress abstracts/posters
Citations excluded: 83 
Reasons: editorials, letters, reviews, re-published articles, IV 
administration to all or some patients
Articles excluded: 45 
Reasons: incomplete renal lab data, pts. with normal renal 
function, baseline SCr > 3.5 mg/dL, CM not identified / 
pooled by class, use of ionic agent
Fig. 1. Study selection diagram.
with more severe renal compromise [17, 23, 29]. There
were differences in other baseline characteristics among
the various CM tested. The iodixanol patients received
slightly more contrast volume (162 vs. 139 mL all others)
and had a greater percentage of diabetic patients (61%
vs. 41% of all others), while iopamidol patients were less
likely to have diabetes (35% vs. 49% all others), and
the iopamidol and iohexol patients received less contrast
volume (126–128 mL vs. 151 mL of all others). These
differences were influenced by two individual studies in-
volving iodixanol, the NEPHRIC study [16], which in-
cluded 100% diabetics, and the RAPPID study [20], in
which a high volume of contrast media was administered
(222 mL).
Table 2 shows details about the hydration protocols
and contrast exposure in the different primary studies. No
data about hydration were available for the comparison
between iodixanol and iohexol conducted by Chalmers
et al [17]. In general, vigorous hydration was used in all
the other studies, as recommended in patients with renal
impairment. Doses of contrast were in general >100 mL,
except in the study by Chalmers et al (53–60 mL for io-
hexol and iodixanol, respectively) [17] and in the study
by Durham et al for iohexol (85 ± 42 mL) [19].
The CIN incidence in the different studies is reported
in Table 3. CIN was defined as an absolute SCr increase
of 0.5 mg/dL or above in 10 studies [13, 14, 17, 18, 21–
23, 25–27]. Five studies used a relative SCr increase by
25% or greater as end point for CIN [20, 24, 27, 28,
31]. In most cases, the post-CM measurement of SCr oc-
curred at 48 to 72 hours after the angiographic procedure
[7, 13, 14, 17, 21–28, 31]. In two studies, SCr measurement
was performed at 1 to 7 days following the intra-arterial
administration of the contrast agents, and the maximum
SCr value was used for CIN assessment [18, 20]. Over-
all, there were 230 cases of CIN in the primary studies
involving 1365 high-risk patients (overall CIN incidence
of 16.8%).
Table 4 presents the results of the logistic regression
analysis. The adjusted odds ratios from the model showed
that the risk of CIN is similar with iopamidol (OR 0.318,
95% CI 0.19-0.533) and iodixanol (OR 0.262, 95% CI
0.156-0.438). Both iopamidol and iodixanol showed a
significantly lower risk of CIN compared to iohexol.
Baseline SCr levels, CM volume, and age appeared to sig-
nificantly increase the risk of CIN in the selected study
population, while diabetes mellitus and gender distribu-
tion did not. All these factors were adjusted to keep con-
sistency in the model so that the above comparison among
contrast media more accurately reflected the true treat-
ment effect on the incidence of CIN.
The incidence of CIN was 10% to 37% with iohexol
[13, 16–19], 3% to 21% with iodixanol [16, 17, 20, 21],
6% to 25% with iopamidol [14, 22–24, 27, 30], 45% with
ioxilan [25], 11% to 13% with iopromide [26], 20% with
iomeprol [28], and 50% with iopentol [29] (Fig. 2).
No major differences were observed in the incidence
of CIN (16.8% all studies) by excluding iopromide,
iomeprol, or ioxilan from the group of the nonionic
monomers because of the limited sample size of the
studies with those agents (iopromide excluded: 214/1229,
17.4%; ioxilan excluded: 217/1336, 16.2%; iomeprol ex-
cluded: 220/1315, 16.7%). The exclusion of iopentol led to
a more marked decrease in CIN incidence (from 16.8%
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Table 3. Incidence of contrast-induced nephropathy (CIN), by
contrast medium
Number of CIN
Total number patients with incidence
Contrast medium of patients CIN (%)
Iohexol 431 93 21.58
All other (w/o Iohexol) 934 137 14.67
All other (w/o Iohexol 671 112 16.69
and Iodixanol)
Iodixanol 263 25 9.51
All other (w/o Iodixanol) 1102 205 18.60
Iopamidol 400 45 11.25
All other (w/o Iopamidol) 965 185 19.17
All other (w/o Iopamidol 702 160 22.79
and Iodixanol)
Other contrast mediaa 271 67 24.72
All contrast media 1365 230 16.85
aIopromide, ioxilan, iopentol, and iomeprol.
Table 4. Logistic regression analysis: CM and baseline risk factors
Coefficient Odds Ratio and
Parameter estimate P value 95% CI
CM
Iopamidol −0.4011 0.0367 0.318 (0.19, 0.533)
Iodixanol −0.5958 0.0019 0.262 (0.156, 0.438)
Other 0.2522 0.1295 0.611 (0.376, 0.993)
Iohexol Reference 1.00
Age years 0.1052 0.0007 1.111 (1.045, 1.181)
Gender (% male) −0.0042 0.7138 0.996 (0.974, 1.018)
Diabetes mellitus% −0.00633 0.3349 0.994 (0.981, 1.007)
Baseline SCr mg/dL 0.3487 0.0217 1.417 (1.052, 1.909)
Volume of CM 0.00809 <.0001 1.008 (1.004, 1.012)
administered mL
to 15.4%) because of the high rate of CIN in the study by
Marenzi et al (28/56, 50%) [29]. It should be noted that the
patients in that study had severe preexistent compromise
of renal function (mean baseline SCr 3.1 ± 1.0 mg/dL;
mean CrCl 26 ± 8 mL/min) and received very high doses
of contrast (258 ± 132 mL on average).
Table 4 shows the incidence of CIN by CM. The inci-
dence of CIN with iohexol was 21.6% (93/431). When the
iohexol data were excluded, the CIN incidence dropped
from 16.9% to 14.7% (137/934). The incidence of CIN
with iohexol was significantly higher than the incidence
of CIN with all the other agents (21.6% vs. 14.7%, P =
0.0015, RR 1.47, 95% CI 1.16-1.87). Also, the incidence of
CIN with iohexol was higher compared to that observed
with all the other nonionic monomers (21.6% vs. 16.7%,
P = 0.0419, RR 1.29, CI 1.01-1.65).
The incidence of CIN with iopamidol was 11.3%
(45/400). When the iopamidol data were excluded from
the analysis, the CIN incidence following all the other
nonionic agents went up to 19.2% (185/965). The inci-
dence of CIN with iopamidol was significantly lower than
the incidence of CIN with all the other agents (11.3% vs.
19.7%, P = 0.0004, RR 0.59, 95% CI 0.43-0.80). Also, the
incidence of CIN with iopamidol was significantly lower
than the incidence of CIN with all the other nonionic
monomers (11.3% vs. 22.8%, P < 0.0001, RR 0.49, CI
0.36-0.67).
Significant differences were also observed between
iopamidol and iohexol (11.3% vs. 21.6%, P = 0.0001, RR
0.52, 95% CI 0.38-0.72), and between iodixanol and io-
hexol (9.5% vs. 21.6%, P < 0.0001, RR 0.44, CI 0.29-0.67).
DISCUSSION
The results of our analysis suggest that differences in
the incidence of CIN among contrast media cannot be ex-
plained solely by differences in CM osmolality. In a previ-
ous metaanalysis, Barrett el al found no difference in the
incidence of CIN between agents of different osmolality
except in those with preexisting renal insufficiency (cre-
atinine >1.35 mg/dL or estimated GFR <70 mL/min).
However, the Barrett analysis did not include any stud-
ies with iso-osmolality CM and did not take into account
the level of renal insufficiency or the volume of CM ad-
ministered [15]. The current analysis extends the range of
CM to include iso-osmolality and attempts to control for
additional risk factors, such as age, gender, presence of
diabetes, volume of CM administered, and baseline SCr,
which could independently contribute to the incidence of
CIN.
The mechanism of CIN is multifactorial. Experimental
studies suggest that CIN is due to both a direct toxic ef-
fect on the renal tubular epithelial cells and to contrast-
induced renal medullary ischemia. The contribution of
CM osmolality to the pathogenesis of CIN is unclear. An-
imal and in vitro experiments with hypertonic saline and
mannitol support a role for hyperosmolality in causing di-
rect renal cell injury and decreases in renal blood flow and
GFR [32]. However, these studies were conducted with
solutes at osmolalities >1500 mOsm/kg. More recent in
vitro experiments with mannitol at osmolalities <1000
indicate a much reduced toxic effects relative to CM
of the same osmolality [33–35]. These observations are
supported by in vitro studies with different CMs. These
studies suggest that factors other than osmolality (such
as viscosity, hydrophylicity) may contribute to the toxic
effect of CM [36–40]. It is noteworthy that iohexol was
found to be more toxic than other nonionic monomers on
proximal tubule vacuolization [41, 42] and capillary con-
gestion [42]. The relationship of these histologic changes
to the functional changes in RBF and GFR is unclear.
Our analysis suggests that iodixanol, an iso-osmolality
agent (290 mOsm/kg), is associated with a lower inci-
dence of CIN compared to iohexol (844 mOsm/kg) (see
Table 2). However, iodixanol does not appear to be signif-
icantly less nephrotoxic than another low osmolality CM,
iopamidol (796 mOsm/kg). Observed differences in the
incidence of CIN with different CM were not explained
by differences in patient age, baseline renal function, or
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Fig. 2. Incidence of contrast-induced
nephropathy in patients with chronic renal in-
sufficiency receiving nonionic contrast agents
in various prospective studies (iohexol, data
extracted from [13, 16–19]; iodixanol, data
extracted from [16, 17, 20, 21]; iopamidol,
data extracted from [14, 22–24]; ioxilan,
data extracted from [25]; iopromide, data
extracted from [26]; iomeprol, data extracted
from [27]; iopentol, data extracted from
[28]).
volume of CM administered. This suggests that charac-
teristics of the individual contrast agents in addition to
osmolality may be important in causing nephrotoxicity.
This conclusion is supported by animal studies that have
found that the direct tubular toxicity of iohexol is signif-
icantly greater than that of iopamidol and other CM of
similar osmolality [41, 42]. In our analysis, iohexol was
indeed associated with a higher incidence of CIN com-
pared to all other low osmolality agents (21.6% vs. 16.7%,
P <.0.0419).
The viscosity of the contrast solution may play an ad-
ditional role in contributing to the fall in glomerular fil-
tration rate and renal medullary blood flow. It has been
suggested that the higher viscosity of iodixanol may cause
a reduced transit time of these agents in the renal tubules
and subsequent increased tubular pressures, which in turn
can cause a decrease in glomerular filtration rate [39].
The iso-osmolality nonionic dimers have been reported
to cause more red blood cell aggregation and cessation
of flow in the renal microcirculation [43], and more re-
duction in medullary renal blood flow [36, 37] than hy-
perosmolality agents in animal models. It may be that
both osmolality and viscosity contribute to nephrotox-
icity. This may explain why iodixanol, a CM isotonic to
human plasma but with a high viscosity, has a similar inci-
dence of CIN compared to iopamidol, a CM hypertonic
to plasma but with a low viscosity. It may also explain
why iohexol has a higher incidence of CIN relative to
iopamidol.
LIMITATIONS
This analysis is not a traditional meta-analysis made
up of randomized comparisons between two treatment
groups. We attempted to identify all available studies ref-
erencing the rate of CIN with the use of a single CM.
As such, we included studies that were not randomized
comparisons between two different CM. Such head-to-
head comparison studies have the advantage that the
randomization process should distribute known and un-
known confounding variables equally. This strengthens
any conclusion that differences in the incidence of CIN
are attributable to the CM. Without the benefit of such
a randomization procedure, we attempted to account for
the known confounders by meta-regression using study
level mean data. The strength of this approach is that it
accounts for the most well-known risk factors for CIN.
Although we attempted to adjust for the known risk
factors for CIN (age, presence of diabetes mellitus,
degree of baseline renal insufficiency, volume of CM ad-
ministered), we could not account for possible interac-
tions between these risk factors. Most of the patients in
this analysis underwent cardiac angiography or interven-
tions, so it is likely that the highest concentration of iodine
(mgI/mL) available for each agent was used. However,
several studies did not reference the concentration of the
CM used. Finally, because we analyzed studies employing
intra-arterial injection of CM, this analysis does not ad-
dress potential differences among CM in the risk of CIN
following their intravenous administration.
CONCLUSION
Meta-regression analysis of the available data on the
incidence of CIN in high-risk patients following intraarte-
rial administration of low- or iso-osmolality CM suggests
that the osmolality of the contrast agent alone does not
account for the differences in the incidence of CIN. While
earlier data suggested a role for osmolality in the patho-
genesis of CIN at high osmolalities (>1000 mOsm/kg),
our analysis suggests that either osmolality in the range
of 290 to approximately 800 is not toxic to the kidney, or
that for CM within this range of osmolality other char-
acteristics of CMs, such as viscosity or direct molecular
toxicity, play a greater role in the development of CIN.
Future prospective clinical trials comparing individual
Solomon: Role of osmolality in CIN 2263
low- and iso-osmolality CMs in high-risk patients will help
to further explore the role of osmolality and viscosity in
CIN.
Reprint requests to Richard Solomon, M.D., Fletcher Allen Health
Care, Burlington, VT.
E-mail: richard.solomon@vtmednet.org
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